Amneal Pharmaceuticals(NASDAQ) AMRX

Amneal Pharmaceuticals, Inc. makes affordable medicines for everyday use. It helps patients manage Parkinson's disease and other health conditions. The company also supplies medical products to government agencies.

Pills, Patches, and Prowess

• Affordable Medicines: Retail generic drugs, injectable medicines, and biosimilars; net revenue was $489.9 million for the three months ended June 30, 2026.
• Specialty Portfolio: Branded treatments for neurological conditions and endocrine disorders; net revenue was $149.3 million for the three months ended June 30, 2026.
• AvKARE: Distribution services for the U.S. federal government and retail pharmacies; net revenue was $157.0 million for the three months ended June 30, 2026.

Growing Beyond Generics

• Agreed to acquire Kashiv BioSciences in April 2026 to add advanced clinical-stage assets and biosimilar manufacturing capacity.
• Launched new products in 2025 and 2026 that contributed $44.8 million to revenue growth during the second quarter of 2026.
• Introduced the Crexont and Brekiya autoinjector branded products to the specialty market.
• Reduced interest rates on its variable-rate debt through a repricing amendment in August 2026.

A Global Infrastructure

Amneal operates its primary manufacturing and distribution facilities in the United States, India, and Ireland. Its development team focuses on creating complex medicine formats like transdermal patches, inhalants, and injectable solutions.

Performance by the Numbers

• Net revenue was $796.2 million in the second quarter of 2026, up 9.9% year over year.
• Net income was $69.6 million in the second quarter of 2026, up 95.5% year over year.
• Gross profit as a percentage of net revenue was 42.0% for the second quarter of 2026, up from 39.5% year over year.
• Cash used in operating activities was $48.0 million for the six-month period ended June 30, 2026.
• The company estimates that water damage at one India facility in July 2026 could cost $10 million to $15 million for repairs and inventory losses.

The Bottom Line

Amneal has evolved from a generic drug manufacturer into a diversified pharmaceutical business with branded and distribution arms. Recent acquisitions and product launches have expanded its reach into complex biological medicines and specialized treatments.